AU2021273487A1 - Combination treatment of liver disorders - Google Patents
Combination treatment of liver disorders Download PDFInfo
- Publication number
- AU2021273487A1 AU2021273487A1 AU2021273487A AU2021273487A AU2021273487A1 AU 2021273487 A1 AU2021273487 A1 AU 2021273487A1 AU 2021273487 A AU2021273487 A AU 2021273487A AU 2021273487 A AU2021273487 A AU 2021273487A AU 2021273487 A1 AU2021273487 A1 AU 2021273487A1
- Authority
- AU
- Australia
- Prior art keywords
- agonist
- compound
- thrp
- patient
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024360P | 2020-05-13 | 2020-05-13 | |
| US63/024,360 | 2020-05-13 | ||
| PCT/US2021/032085 WO2021231646A1 (en) | 2020-05-13 | 2021-05-12 | Combination treatment of liver disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021273487A1 true AU2021273487A1 (en) | 2023-01-05 |
Family
ID=78524975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021273487A Pending AU2021273487A1 (en) | 2020-05-13 | 2021-05-12 | Combination treatment of liver disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210379043A1 (enExample) |
| EP (1) | EP4149452A4 (enExample) |
| JP (1) | JP2023525571A (enExample) |
| KR (1) | KR20230024277A (enExample) |
| CN (1) | CN115811972A (enExample) |
| AU (1) | AU2021273487A1 (enExample) |
| BR (1) | BR112022023048A2 (enExample) |
| CA (1) | CA3183413A1 (enExample) |
| IL (1) | IL298144A (enExample) |
| MX (1) | MX2022014238A (enExample) |
| TW (1) | TW202207928A (enExample) |
| WO (1) | WO2021231646A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| PE20231096A1 (es) | 2020-08-25 | 2023-07-18 | Lilly Co Eli | Polimorfos de un inhibidor de ssao |
| WO2022165227A1 (en) * | 2021-02-01 | 2022-08-04 | Madrigal Pharmaceuticals, Inc. | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders |
| TW202315608A (zh) * | 2021-07-06 | 2023-04-16 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
| TWI845975B (zh) * | 2021-07-06 | 2024-06-21 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
| AU2022387121A1 (en) * | 2021-11-11 | 2024-06-20 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| MX2024005647A (es) * | 2021-11-11 | 2024-05-24 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2170403T1 (sl) * | 2007-06-27 | 2014-07-31 | Quark Pharmaceuticals, Inc. | Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov |
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CA2944139C (en) * | 2014-04-11 | 2020-11-03 | Cymabay Therapeutics, Inc. | Treatment of nafld and nash |
| JP7618384B2 (ja) * | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| ES3029158T3 (en) * | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| EP3844156A4 (en) * | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISEASES |
| US20220047553A1 (en) * | 2018-09-18 | 2022-02-17 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
| CN121081472A (zh) * | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
-
2021
- 2021-05-12 WO PCT/US2021/032085 patent/WO2021231646A1/en not_active Ceased
- 2021-05-12 JP JP2022568965A patent/JP2023525571A/ja active Pending
- 2021-05-12 AU AU2021273487A patent/AU2021273487A1/en active Pending
- 2021-05-12 US US17/318,994 patent/US20210379043A1/en not_active Abandoned
- 2021-05-12 EP EP21803928.7A patent/EP4149452A4/en active Pending
- 2021-05-12 CN CN202180047741.3A patent/CN115811972A/zh active Pending
- 2021-05-12 KR KR1020227043095A patent/KR20230024277A/ko not_active Ceased
- 2021-05-12 IL IL298144A patent/IL298144A/en unknown
- 2021-05-12 MX MX2022014238A patent/MX2022014238A/es unknown
- 2021-05-12 CA CA3183413A patent/CA3183413A1/en active Pending
- 2021-05-12 BR BR112022023048A patent/BR112022023048A2/pt unknown
- 2021-05-13 TW TW110117355A patent/TW202207928A/zh unknown
-
2023
- 2023-01-20 US US18/157,216 patent/US20240000765A1/en not_active Abandoned
-
2024
- 2024-06-03 US US18/732,162 patent/US20240316025A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022014238A (es) | 2023-04-11 |
| TW202207928A (zh) | 2022-03-01 |
| JP2023525571A (ja) | 2023-06-16 |
| US20240316025A1 (en) | 2024-09-26 |
| CN115811972A (zh) | 2023-03-17 |
| EP4149452A1 (en) | 2023-03-22 |
| CA3183413A1 (en) | 2021-11-18 |
| WO2021231646A1 (en) | 2021-11-18 |
| KR20230024277A (ko) | 2023-02-20 |
| BR112022023048A2 (pt) | 2022-12-20 |
| US20210379043A1 (en) | 2021-12-09 |
| IL298144A (en) | 2023-01-01 |
| US20240000765A1 (en) | 2024-01-04 |
| EP4149452A4 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240000765A1 (en) | Combination treatment of liver disorders | |
| EP4149453A1 (en) | Combination treatment of liver disorders | |
| US20230241071A1 (en) | Combination treatment of liver disorders | |
| US11897875B2 (en) | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders | |
| US20230181583A1 (en) | Treating liver disorders with an ssao inhibitor | |
| KR20240101642A (ko) | THR-β 작용제를 이용한 간 장애의 치료 | |
| AU2020380968A1 (en) | Treating liver disorders | |
| AU2004275852A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
| US20220387414A1 (en) | Treating liver disorders | |
| US20200276186A1 (en) | Use of morphinans for treating cocaine addiction, pruritis, and seizure disorders |